European Neuropsychopharmacology
Volume 20, Issue 8 , Pages 562-567 , August 2010

Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis

  • Enrico Tedeschini

      Affiliations

    • Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    • Department of Psychiatry, University of Modena and Reggio Emilia, Modena, Italy
    • Corresponding Author InformationCorresponding author. Depression Clinical and Research Program, Massachusetts General Hospital, 50 Staniford Street, Boston, Massachusetts 02114, USA. Tel.: +1 617 513 6821; fax: +1 617 726 7541.
    • ,
  • Maurizio Fava

      Affiliations

    • Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • Tracie M. Goodness

      Affiliations

    • Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • George I. Papakostas

      Affiliations

    • Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Received 10 November 2009 ,Revised 14 January 2010 ,Accepted 3 February 2010.

References 

  1. American Psychiatric Association. and American Psychiatric Association. Task Force on DSM-IV . In: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, D.C.: American Psychiatric Association; 1994;p. xxvii
  2. American Psychiatric Association. Task Force on Nomenclature and Statistics. and American Psychiatric Association. Committee on Nomenclature and Statistics . In: Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Assn.; 1980;p. 494
  3. American Psychiatric Association. Work Group to Revise DSM-III . In: Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. Washington, DC: American Psychiatric Association; 1987;p. xxix
  4. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur. Neuropsychopharmacol. 2006;16:601
  5. Demitrack MA, Faries D, Herrera JM, DeBrota D, Potter WZ. The problem of measurement error in multisite clinical trials. Psychopharmacol. Bull. 1998;34:19
  6. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J. Psychiatr. Res. 2000;34:3
  7. Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J. Clin. Psychopharmacol. 2001;21:561
  8. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother. Psychosom. 2003;72:115
  9. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch. Gen. Psychiatry. 1972;26:57
  10. Guy, W., National Institute of Mental Health (U.S.). Psychopharmacology Research Branch. and Early Clinical Drug Evaluation Program., 1976, ECDEU assessment manual for psychopharmacology (U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, Md.) 603 pp.
  11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56
  12. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003;28:552
  13. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol. Psychiatry. 2007;62:65
  14. Lee S, Walker JR, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress. Anxiety. 2004;19:10
  15. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol. Psychiatry. 2006;59:1001
  16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382
  17. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharmacol. 2009;19:34
  18. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol. Psychiatry. 2000;47:736
  19. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, et al Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am. J. Psychiatry. 1991;148:997
  20. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch. Gen. Psychiatry. 1978;35:773
  21. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J. Clin. Psychiatry. 2006;67:1741
  22. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. Neuropsychopharmacology. 1994;11:33
  23. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. Jama. 2002;287:1840
  24. Wernicke JF, Sayler ME, Koke SC, Pearson DK, Tollefson GD. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depress. Anxiety. 1997;6:31

PII: S0924-977X(10)00023-4

doi: 10.1016/j.euroneuro.2010.02.004

European Neuropsychopharmacology
Volume 20, Issue 8 , Pages 562-567 , August 2010

Article Tools

* Image Usage & Resolution